Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger

Core Insights - Pyxis Oncology, Inc. has appointed Michael A. Metzger to its Board of Directors, effective June 10, 2024, bringing over 25 years of biopharmaceutical experience [1][3] - The company focuses on developing next-generation therapeutics aimed at difficult-to-treat cancers, with ongoing Phase 1 clinical studies for its candidates PYX-201 and PYX-106 [4] Company Overview - Pyxis Oncology is a clinical-stage company dedicated to creating therapeutics that can target and treat challenging cancers [4] - The company is developing antibody-drug conjugates (ADCs) and immuno-oncology programs that utilize innovative strategies to address solid tumors resistant to current treatments [4] Leadership and Strategy - Michael A. Metzger has a strong background in the biopharmaceutical sector, having held senior leadership roles and served on various boards, including his current position as CEO of Syndax Pharmaceuticals [3] - The leadership at Pyxis Oncology believes that Metzger's expertise will be crucial in advancing the company's mission to improve cancer treatment outcomes [7]